To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Overweight Social Drinkers.

This study is currently recruiting participants.
Verified October 2013 by GlaxoSmithKline
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01738867
First received: November 28, 2012
Last updated: October 31, 2013
Last verified: October 2013
  Purpose

Total 48 overweight to obese subjects with a history of social drinking will be recruited into this single-centre, randomized, double-blind, cross-over study. Subjects will be genetically stratified to result in equal numbers of A118G 'AA' homozygotes (n=24) and A118G 'G' carriers (n=24).

Subjects will participate in all three treatment periods and will be randomized to receive each of the following for 5 days: Treatment A: Placebo, Treatment B: Naltrexone (NTX) 50 mg once daily (25 mg once daily for the first two days) and Treatment C: GSK1521498 10 mg once daily. A washout period will be of at least 14 days between treatments. Subjects will return for a follow-up visit 7-10 days after the final treatment session washout period has been completed.

Participants will attend the clinical research unit on days 1, 2, 4 and 5 to monitor safety and tolerability for both drugs. Participants will attend the clinical unit on days 4 and 5 for a two day assessment, using a series of pharmacodynamic measurements known to be sensitive to the effects of GSK1521498 and/or NTX: Functional brain response to alcohol and food cues; plasma cortisol; hedonic and consummatory eating behaviors; subjective response to an ethanol challenge; experimental pain threshold; and cognitive tests of attention bias towards alcohol and food cues.


Condition Intervention Phase
Alcoholism
Drug: GSK1521498
Drug: Naltrexone (NTX)
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Overweight Social Drinkers.

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Brain activation within the reward circuitry in response to consumption of food and alcohol cues, as measured by functional magnetic resonance imaging (fMRI) [ Time Frame: 5 Days in each treatment period ] [ Designated as safety issue: No ]
    To test that the OPRM1 A118G polymorphism modulates the effects of GSK1521498 10 mg on brain reward function and processing

  • Adverse events as a measure of safety and tolerability [ Time Frame: Throughout the study, from Day 1 to Day 67 ] [ Designated as safety issue: No ]
    Number of subjects with any adverse events during the treatment periods

  • Blood pressure (BP) as a measure of safety and tolerability [ Time Frame: Day 1, Day 2, Day 5 in each treatment period and Follow-up visit. ] [ Designated as safety issue: No ]
    Systolic and diastolic BP will be measured

  • 12-lead ECG and heart rate as a measure of safety and tolerability [ Time Frame: Day 1, Day 2, Day 5 in each treatment period and Follow-up visit. ] [ Designated as safety issue: No ]
    12-lead electrocardiograph (ECG) will be measured

  • Clinical chemistry including liver enzymes and hematology as a measure of safety and tolerability [ Time Frame: Screening (Up to 30 days prior to Day 1),Day 5of each of the 3 treatment periods and Follow-up visit ] [ Designated as safety issue: No ]
    Hematology/Chemistry labs to be done at screening (fasted) and day 5 for each treatment session (un-fasted).

  • Psychiatric symptom questionnaires-Becks Depression & Anxiety Inventory (BDI-II &BAI) [ Time Frame: Day 1 (pre-dose on and approx 4 hours post dose), Day 2 (prior to discharge), Day 3 (at home), Day 5 (prior to discharge), in each treatment period and Follow-up visit. ] [ Designated as safety issue: No ]
    Mood anxiety will be assessed by The Beck Anxiety Inventory (BAI), The Beck Depression Inventory (BDI-II).

  • Psychiatric symptom questionnaires- Columbia Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Day 1 (pre-dose on and approx 4 hours post dose), Day 2 (prior to discharge), Day 5 (prior to discharge), in each treatment period and Follow-up visit ] [ Designated as safety issue: No ]
    Suicidality will be assessed by C-SSRS.

  • Psychiatric symptom questionnaires- Bond and Lader Visual Analogue Scales (VAS). [ Time Frame: Pre - dose on Day 1 and approx 4 hours post dose on Day 1, prior to discharge on Day 2, at home on Day 3, Day 4, 5 and follow up. ] [ Designated as safety issue: No ]
    Mood anxiety and suicidality will be assessed by VAS.


Secondary Outcome Measures:
  • To test that the OPRM1 A118G polymorphism modulates the effect of GSK1521498 10mg on plasma cortisol [ Time Frame: Day 1 and Day 5 pre-dose, at approximately the same time, and on Day 5 post dose in each treatment period. ] [ Designated as safety issue: No ]
    Plasma cortisol concentrations will be measured under fasting conditions

  • Pressure pain threshold and sensitivity [ Time Frame: Day 4 in each treatment period. ] [ Designated as safety issue: No ]
    Pressure pain threshold and sensitivity will be measured in response to cutaneous pressure. Pressure pain thresholds and tolerance will be assessed at two tender points (left and right trapezius points, as defined by American College of Rheumatology)

  • Consummatory eating behaviour [ Time Frame: Day 5 in each treatment period. ] [ Designated as safety issue: No ]
    Eating behaviour will be assessed by Ad libitum snacking , Menu choices and ad libitum intake of test buffet meals, Appetite Visual Analogue Scales (A-VAS) and Binge Eating Scale (BES)

  • Hedonic taste preference [ Time Frame: Day 5 in each treatment period. ] [ Designated as safety issue: No ]
    Response to sweet and high fat samples (tasting sweetened dairy products), will be performed in a fasted state. The Hedonic 9 point preference scale and Sensory Stimuli Scale will be performed after each sample has been tasted.

  • Subjective responses to intravenous doses of ethanol [ Time Frame: Day 4 in each treatment period ] [ Designated as safety issue: No ]
    It will be measured using self-report questionnaires Biphasic alcohol effects scale (BAES), Subjective High Assessment Scale (SHAS), Profile of Mood States (POMS-B), and Alcohol Rating Scale (ARS)

  • To compare the placebo-controlled effects of GSK1521498 10 mg to the placebo-controlled effects of NTX 50 mg [ Time Frame: Day 5 in each treatment period. ] [ Designated as safety issue: No ]
    The comparison will be done for the all efficacy endpoints as mentioned earlier which include Plasma cortisol; fMRI and cognitive measures of reward processing; pain threshold; hedonic and consummatory eating behaviour, subjective response to ethanol


Estimated Enrollment: 48
Study Start Date: December 2012
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GSK1521498
Subject will receive 10 mg orally once daily for 5 days in one of the 3 treatment periods.
Drug: GSK1521498
White HPMC capsule containing 10 mg of GSK1521498
Experimental: Naltrexone
Subject will receive 25 mg orally once daily for the first two days and 50 mg once daily for 3 days in one of the 3 treatment periods.
Drug: Naltrexone (NTX)
Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX
Placebo Comparator: Placebo
Subject will receive oral dose of matching placebo once daily for 5 days in one of the 3 treatment periods.
Drug: Placebo
Matching placebo capsules to GSK1521498 or NTX

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Caucasian male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent
  • Overweight to obese (Body Mass Index [BMI] greater than or equal to 25 kilogram [kg]/ [meter]m^2) but otherwise healthy as determined by a responsible and experienced physician
  • Self reported alcohol drinking frequency of 3 or more drinks for men (2 or more drinks for women) at least two days per week, on average
  • Aspartate aminotransferase (AST) and alanine transaminase (ALT < 2xULN; alkaline phosphatase and bilirubin <=1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
  • A female subject is eligible to participate if she is of child-bearing potential and is abstinent or agrees to use one of the accepted contraception methods
  • Male subjects with female partners of child-bearing potential must agree to use one of the acceptable contraception methods
  • Capable of giving written informed consent

Exclusion Criteria:

  • Psychiatric illness and substance abuse:
  • Current or past history of DSM-IV alcohol or substance dependence or abuse, including treatment-seeking behaviour, as determined by the Investigator or MINI.
  • Self administered Beck Depression Inventory II scale total score greater than 13 or suicide question score greater than zero at screening.
  • Current or past chronic history of neurological disorders.
  • Current or past history of Axis 1 psychiatric disorders including eating disorders such as anorexia nervosa, bulimia nervosa and binge eating disorder, including treatment seeking behaviour using the MINI.
  • Subject who, in the investigator/designee's judgement, poses a significant suicide risk. Evidence of serious suicide risk may include any history of suicidal behaviour and/or any evidence of suicidal ideation on any questionnaires e.g. type 4 or 5 on the C-SSRS in the last 5 years
  • Concomitant drug use: Positive urine screen for amphetamines, barbiturates, cocaine, opiates, cannabinoids or benzodiazepines at screening.
  • Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 14 days prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety
  • Miscellaneous:
  • Special dietary requirements (e.g. vegetarians, vegans, religious, food -intolerantdiets), cannot be accommodated by the experimental design - it is important that all participants are offered the same test meals and snack choices during their in-unit assessments - so people with special dietary requirements will be excluded.
  • Subjects unsuitable for cannulation.
  • Any contraindications or logistical complications anticipated in relation to MRI scanning or other endpoint assessments, in the judgment of the Principal Investigator, including: presence of a cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies as assessed by a standard pre-MRI questionnaire, claustrophobia, inability to lie still on back for approximately an hour.
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • QTcB or QTcF > 450 msec. Note that if the initial QTc value is prolonged, the ECG should be repeated two more times (with 5 minutes between ECG readings) and the average of the 3 QTc values used to determine eligibility
  • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody or HIV tests result within 3 months of screening.
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • Pregnant or lactating females.
  • Occupational use of heavy machinery.
  • Heavy smokers i.e > 15 cigarettes per day
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01738867

Contacts
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com

Locations
United Kingdom
GSK Investigational Site Recruiting
Cambridge, United Kingdom, CB2 2GG
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01738867     History of Changes
Other Study ID Numbers: 116753
Study First Received: November 28, 2012
Last Updated: October 31, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by GlaxoSmithKline:
Pharmacogenetics
OPRM1
Pharmacodynamics
Addiction
mu opioid receptors

Additional relevant MeSH terms:
Alcoholism
Overweight
Alcohol-Related Disorders
Substance-Related Disorders
Mental Disorders
Body Weight
Signs and Symptoms
Naltrexone
Analgesics, Opioid
Narcotic Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Analgesics
Central Nervous System Depressants

ClinicalTrials.gov processed this record on April 16, 2014